Palvella Therapeutics, Inc. Effective Income Tax Rate Reconciliation, Other Adjustments, Percent
Palvella Therapeutics, Inc. (PVLA) reported Effective Income Tax Rate Reconciliation, Other Adjustments, Percent of -1.00% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments · last filed 2026-03-31
- Palvella Therapeutics, Inc. effective income tax rate reconciliation, other adjustments, percent for fiscal 2025 was -1.00%.
- Palvella Therapeutics, Inc. effective income tax rate reconciliation, other adjustments, percent for fiscal 2024 was 0.00%, a 100.00% decline from fiscal 2023.
- Palvella Therapeutics, Inc. effective income tax rate reconciliation, other adjustments, percent for fiscal 2023 was 0.10%, a 90.00% decline from fiscal 2022.
- Palvella Therapeutics, Inc. effective income tax rate reconciliation, other adjustments, percent for fiscal 2022 was 1.00%.
| Period end | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent 12 month | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent 12 month as first filed |
|---|---|---|
| 2025-12-31 | -1.00% 10-K · filed 2026-03-31 | |
| 2024-12-31 | 0.00% 10-K · filed 2026-03-31 | |
| 2023-12-31 | 0.10% 10-K · filed 2025-03-31 | -1.00% 10-K · filed 2024-03-29 |
| 2022-12-31 | 1.00% 10-K · filed 2024-03-29 | |
| 2021-12-31 | 0.00% 10-K · filed 2023-03-31 | |
| 2020-12-31 | -0.40% 10-K · filed 2022-03-02 | |
| 2019-12-31 | 0.80% 10-K · filed 2021-03-31 | |
| 2018-12-31 | 0.50% 10-K · filed 2020-03-13 | |
| 2017-12-31 | 1.80% 10-K · filed 2019-03-18 | |
| 2016-12-31 | -0.90% 10-K · filed 2018-03-15 | |
| 2015-12-31 | 2.90% 10-K · filed 2017-03-30 | |
| 2014-12-31 | 0.10% 10-K · filed 2016-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |